Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aurinia Pharmaceuticals Inc. (AUPH) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Aurinia Pharmaceuticals Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1600620.
Total stock buying since 2021: $37,880,451.
Total stock sales since 2021: $42,709,955.
Total stock option exercises since 2021: $5,949,093.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 2,900,000 | $26,330,088 | 766,469 | $6,156,644 | 0 | $0 |
| 2024 | 1,200,000 | $10,822,000 | 368,155 | $2,080,250 | 35,826 | $0 |
| 2023 | 20,000 | $178,280 | 86,736 | $829,259 | 61,131 | $0 |
| 2022 | 40,000 | $248,885 | 68,080 | $1,254,638 | 40,000 | $203,200 |
| 2021 | 25,125 | $301,198 | 1,294,000 | $32,389,164 | 1,105,136 | $5,745,893 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 1,300,000 | $13,590,000 | 20,000 | $210,000 | 0 | $0 |
| 2025-03 | 1,200,720 | $9,605,740 | 746,469 | $5,946,644 | 0 | $0 |
| 2025-02 | 399,280 | $3,134,348 | 0 | $0 | 0 | $0 |
| 2024-12 | 1,200,000 | $10,822,000 | 0 | $0 | 0 | $0 |
| 2024-11 | 0 | $0 | 9,798 | $82,596 | 35,826 | $0 |
| 2024-08 | 0 | $0 | 18,249 | $96,902 | 0 | $0 |
| 2024-05 | 0 | $0 | 16,186 | $92,907 | 0 | $0 |
| 2024-03 | 0 | $0 | 277,979 | $1,553,021 | 0 | $0 |
| 2024-02 | 0 | $0 | 45,943 | $254,824 | 0 | $0 |
| 2023-05 | 0 | $0 | 23,288 | $262,035 | 61,131 | $0 |
| 2023-03 | 20,000 | $178,280 | 63,448 | $567,224 | 0 | $0 |
| 2022-11 | 30,000 | $139,800 | 0 | $0 | 0 | $0 |
| 2022-03 | 10,000 | $109,085 | 28,080 | $337,238 | 0 | $0 |
| 2022-01 | 0 | $0 | 40,000 | $917,400 | 40,000 | $203,200 |
| 2021-12 | 1,600 | $32,064 | 0 | $0 | 0 | $0 |
| 2021-11 | 0 | $0 | 490,000 | $14,860,300 | 319,000 | $2,013,520 |
| 2021-10 | 0 | $0 | 130,000 | $3,867,500 | 95,000 | $304,000 |
| 2021-09 | 0 | $0 | 546,500 | $11,702,289 | 496,136 | $2,558,938 |
| 2021-08 | 0 | $0 | 77,500 | $1,281,375 | 0 | $0 |
| 2021-07 | 0 | $0 | 5,000 | $69,300 | 0 | $0 |
| 2021-06 | 0 | $0 | 5,000 | $68,800 | 0 | $0 |
| 2021-05 | 16,025 | $163,960 | 0 | $0 | 60,000 | $181,200 |
| 2021-03 | 5,000 | $65,000 | 40,000 | $539,600 | 40,000 | $120,800 |
| 2021-01 | 2,500 | $40,174 | 0 | $0 | 95,000 | $567,435 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-05 | Tang Kevin | Buy | 200,000 | 11.68 | 2,336,000 |
| 2025-08-04 | Tang Kevin | Buy | 100,000 | 11.34 | 1,134,000 |
| 2025-08-01 | Keenan Greg (Chief Medical Officer) | Sale | 20,000 | 10.50 | 210,000 |
| 2025-08-01 | Tang Kevin | Buy | 1,000,000 | 10.12 | 10,120,000 |
| 2025-03-07 | Keenan Greg (Chief Medical Officer) | Sale | 8,305 | 8.23 | 68,350 |
| 2025-03-04 | Robertson Stephen P. (EVP, General Counsel) | Sale | 57,607 | 7.92 | 456,247 |
| 2025-03-04 | Miller Joseph M (Chief Financial Officer) | Sale | 56,154 | 7.92 | 444,739 |
| 2025-03-04 | Donley Matthew Maxwell (Chief Operating Officer) | Sale | 58,991 | 7.92 | 467,208 |
| 2025-03-04 | Greenleaf Peter (Chief Executive Officer) | Sale | 164,947 | 7.92 | 1,306,380 |
| 2025-03-04 | Tang Kevin | Buy | 748,038 | 8.00 | 5,986,548 |
| 2025-03-03 | Keenan Greg (Chief Medical Officer) | Sale | 12,239 | 8.00 | 97,912 |
| 2025-03-03 | Robertson Stephen P. (EVP, General Counsel) | Sale | 64,872 | 8.00 | 518,976 |
| 2025-03-03 | Miller Joseph M (Chief Financial Officer) | Sale | 61,859 | 8.00 | 494,872 |
| 2025-03-03 | Donley Matthew Maxwell (Chief Operating Officer) | Sale | 65,902 | 8.00 | 527,216 |
| 2025-03-03 | Greenleaf Peter (Chief Executive Officer) | Sale | 195,593 | 8.00 | 1,564,744 |
| 2025-03-03 | Tang Kevin | Buy | 452,682 | 8.00 | 3,619,192 |
| 2025-02-28 | Tang Kevin | Buy | 399,280 | 7.85 | 3,134,348 |
| 2024-12-09 | Tang Kevin | Buy | 500,000 | 9.09 | 4,545,000 |
| 2024-12-06 | Tang Kevin | Buy | 400,000 | 9.01 | 3,604,000 |
| 2024-12-05 | Tang Kevin | Buy | 300,000 | 8.91 | 2,673,000 |
| 2024-11-11 | Smith Karen L. (Director) | Sale | 5,241 | 8.43 | 44,181 |
| 2024-11-11 | Bailey Jeffrey Allen (Director) | Sale | 4,557 | 8.43 | 38,415 |
| 2024-11-08 | Smith Karen L. (Director) | Option Ex | 17,913 | .00 | 0 |
| 2024-11-08 | Bailey Jeffrey Allen (Director) | Option Ex | 17,913 | .00 | 0 |
| 2024-08-06 | Habig Scott Michael (Chief Commercial Officer) | Sale | 18,249 | 5.31 | 96,902 |
| 2024-05-21 | Mackay-dunn R. Hector (Director) | Sale | 5,630 | 5.74 | 32,316 |
| 2024-05-21 | Jayne David R.w. (Director) | Sale | 4,946 | 5.74 | 28,390 |
| 2024-05-21 | Leversage Jill (Director) | Sale | 5,610 | 5.74 | 32,201 |
| 2024-03-06 | Habig Scott Michael (Chief Commercial Officer) | Sale | 17,777 | 5.60 | 99,551 |
| 2024-03-06 | Robertson Stephen P. (EVP, General Counsel) | Sale | 57,745 | 5.60 | 323,372 |
| 2024-03-06 | Miller Joseph M (Chief Financial Officer) | Sale | 34,811 | 5.60 | 194,941 |
| 2024-03-06 | Donley Matthew Maxwell (EVP, Ops & Strategy) | Sale | 40,665 | 5.51 | 224,064 |
| 2024-03-06 | Greenleaf Peter (Chief Executive Officer) | Sale | 126,981 | 5.60 | 711,093 |
| 2024-02-27 | Knappertz Volker (EVP, Research and Development) | Sale | 4,930 | 6.10 | 30,073 |
| 2024-02-20 | Habig Scott Michael (Chief Commercial Officer) | Sale | 15,867 | 5.48 | 86,951 |
| 2024-02-20 | Knappertz Volker (EVP, Research and Development) | Sale | 25,146 | 5.48 | 137,800 |
| 2023-05-23 | Mackay-dunn R. Hector (Director) | Sale | 4,818 | 11.26 | 54,250 |
| 2023-05-23 | Jayne David R.w. (Director) | Sale | 8,733 | 11.26 | 98,333 |
| 2023-05-23 | Billen Daniel (Director) | Sale | 4,650 | 11.26 | 52,359 |
| 2023-05-23 | Leversage Jill (Director) | Sale | 4,815 | 11.26 | 54,216 |
| 2023-05-19 | Hagan Joseph P (Director) | Sale | 272 | 10.58 | 2,877 |
| 2023-05-18 | Balakrishnan Brinda (Director) | Option Ex | 8,733 | .00 | 0 |
| 2023-05-18 | Mackay-dunn R. Hector (Director) | Option Ex | 8,733 | .00 | 0 |
| 2023-05-18 | Jayne David R.w. (Director) | Option Ex | 8,733 | .00 | 0 |
| 2023-05-18 | Billen Daniel (Director) | Option Ex | 8,733 | .00 | 0 |
| 2023-05-18 | Leversage Jill (Director) | Option Ex | 8,733 | .00 | 0 |
| 2023-05-18 | Hagan Joseph P (Director) | Option Ex | 8,733 | .00 | 0 |
| 2023-05-18 | Milne George M Jr (Director) | Option Ex | 8,733 | .00 | 0 |
| 2023-03-02 | Robertson Stephen P. (EVP, General Counsel) | Sale | 19,402 | 8.94 | 173,453 |
| 2023-03-02 | Miller Joseph M (Chief Financial Officer) | Sale | 11,296 | 8.94 | 100,986 |
| 2023-03-02 | Greenleaf Peter (Chief Executive Officer) | Sale | 32,750 | 8.94 | 292,785 |
| 2023-03-02 | Milne George M Jr | Buy | 20,000 | 8.91 | 178,280 |
| 2022-11-21 | Donley Matthew Maxwell (Ex VP, Internal Operations) | Buy | 20,000 | 4.66 | 93,200 |
| 2022-03-09 | Mackay-dunn R. Hector | Buy | 5,000 | 11.00 | 54,985 |
| 2022-03-04 | Milne George M Jr | Buy | 5,000 | 10.82 | 54,100 |
| 2022-03-02 | Solomons Neil (Chief Medical Officer) | Sale | 4,846 | 12.01 | 58,200 |
| 2022-03-02 | Martin Michael Robert (Chief Business Officer) | Sale | 4,849 | 12.01 | 58,236 |
| 2022-03-02 | Colao Massimilano (Chief Commercial Officer) | Sale | 3,205 | 12.01 | 38,492 |
| 2022-03-02 | Miller Joseph M (Chief Financial Officer) | Sale | 3,060 | 12.01 | 36,750 |
| 2022-03-02 | Donley Matthew Maxwell (Ex VP, Intern'l Operations) | Sale | 3,052 | 12.01 | 36,654 |
| 2022-03-02 | Greenleaf Peter (Chief Executive Officer) | Sale | 9,068 | 12.01 | 108,906 |
| 2022-01-03 | Hagan Joseph P | Sale | 40,000 | 22.93 | 917,400 |
| 2022-01-03 | Hagan Joseph P | Option Ex | 40,000 | 5.08 | 203,200 |
| 2021-12-13 | Leversage Jill | Buy | 1,600 | 20.04 | 32,064 |
| 2021-11-11 | Solomons Neil (Chief Medical Officer) | Sale | 100,000 | 28.89 | 2,889,000 |
| 2021-11-11 | Solomons Neil (Chief Medical Officer) | Option Ex | 100,000 | 5.30 | 530,000 |
| 2021-11-11 | Martin Michael Robert (Chief Business Officer) | Sale | 40,000 | 29.16 | 1,166,400 |
| 2021-11-11 | Martin Michael Robert (Chief Business Officer) | Option Ex | 29,000 | 18.38 | 533,020 |
| 2021-11-10 | Solomons Neil (Chief Medical Officer) | Sale | 100,000 | 30.86 | 3,086,000 |
| 2021-11-10 | Solomons Neil (Chief Medical Officer) | Option Ex | 100,000 | 5.68 | 568,000 |
| 2021-11-10 | Martin Michael Robert (Chief Business Officer) | Sale | 60,000 | 30.91 | 1,854,300 |
| 2021-11-09 | Solomons Neil (Chief Medical Officer) | Sale | 50,000 | 30.17 | 1,508,500 |
| 2021-11-09 | Martin Michael Robert (Chief Business Officer) | Sale | 50,000 | 30.17 | 1,508,500 |
| 2021-11-01 | Solomons Neil (Chief Medical Officer) | Sale | 45,000 | 31.64 | 1,423,800 |
| 2021-11-01 | Solomons Neil (Chief Medical Officer) | Option Ex | 45,000 | 5.30 | 238,500 |
| 2021-11-01 | Martin Michael Robert (Chief Business Officer) | Sale | 45,000 | 31.64 | 1,423,800 |
| 2021-11-01 | Martin Michael Robert (Chief Business Officer) | Option Ex | 45,000 | 3.20 | 144,000 |
| 2021-10-25 | Huizinga Robert Bindert (EVP of Research) | Sale | 130,000 | 29.75 | 3,867,500 |
| 2021-10-25 | Huizinga Robert Bindert (EVP of Research) | Option Ex | 95,000 | 3.20 | 304,000 |
| 2021-09-21 | Huizinga Robert Bindert (EVP of Research) | Sale | 32,500 | 23.86 | 775,287 |
| 2021-09-21 | Huizinga Robert Bindert (EVP of Research) | Option Ex | 27,136 | 2.92 | 79,101 |
| 2021-09-21 | Martin Michael Robert (Chief Business Officer) | Sale | 87,500 | 24.02 | 2,101,750 |
| 2021-09-21 | Martin Michael Robert (Chief Business Officer) | Option Ex | 87,500 | 9.91 | 867,387 |
| 2021-09-20 | Martin Michael Robert (Chief Business Officer) | Sale | 28,500 | 21.66 | 617,167 |
| 2021-09-20 | Martin Michael Robert (Chief Business Officer) | Option Ex | 28,500 | 5.30 | 151,050 |
| 2021-09-14 | Huizinga Robert Bindert (EVP of Research) | Sale | 22,500 | 21.75 | 489,375 |
| 2021-09-14 | Martin Michael Robert (Chief Business Officer) | Sale | 134,000 | 21.48 | 2,864,850 |
| 2021-09-14 | Martin Michael Robert (Chief Business Officer) | Option Ex | 134,000 | 4.78 | 615,700 |
| 2021-09-13 | Solomons Neil (Chief Medical Officer) | Option Ex | 150,000 | 3.20 | 480,000 |
| 2021-09-13 | Martin Michael Robert (Chief Business Officer) | Option Ex | 25,000 | 5.30 | 132,500 |
| 2021-09-10 | Solomons Neil (Chief Medical Officer) | Sale | 150,000 | 19.84 | 2,976,000 |
| 2021-09-10 | Huizinga Robert Bindert (EVP of Research) | Sale | 10,000 | 19.80 | 197,950 |
| 2021-09-10 | Martin Michael Robert (Chief Business Officer) | Sale | 25,000 | 19.80 | 495,000 |
| 2021-09-07 | Huizinga Robert Bindert (EVP of Research) | Sale | 5,000 | 18.30 | 91,500 |
| 2021-09-07 | Martin Michael Robert (Chief Business Officer) | Sale | 7,500 | 18.10 | 135,750 |
| 2021-08-26 | Martin Michael Robert (Chief Business Officer) | Sale | 22,500 | 17.81 | 400,725 |
| 2021-08-25 | Solomons Neil (Chief Medical Officer) | Sale | 5,000 | 15.85 | 79,250 |
| 2021-08-09 | Solomons Neil (Chief Medical Officer) | Sale | 45,000 | 16.03 | 721,350 |
| 2021-08-09 | Martin Michael Robert (Chief Business Officer) | Sale | 5,000 | 16.01 | 80,050 |
| 2021-07-28 | Martin Michael Robert (Chief Business Officer) | Sale | 5,000 | 13.86 | 69,300 |
| 2021-06-22 | Martin Michael Robert (Chief Business Officer) | Sale | 5,000 | 13.76 | 68,800 |
| 2021-05-11 | Huizinga Robert Bindert (Ex Vice President of Research) | Option Ex | 40,000 | 3.02 | 120,800 |
| 2021-05-11 | Martin Michael Robert (Chief Business Officer) | Option Ex | 20,000 | 3.02 | 60,400 |
| 2021-05-11 | Miller Joseph M (Chief Financial Officer) | Buy | 1,000 | 9.74 | 9,740 |
| 2021-05-11 | Donley Matthew Maxwell (Ex VP, Intern'l Operations) | Buy | 9,900 | 10.07 | 99,742 |
| 2021-05-11 | Greenleaf Peter (Chief Executive Officer) | Buy | 5,125 | 10.63 | 54,478 |
| 2021-03-12 | Solomons Neil (Chief Medical Officer) | Sale | 40,000 | 13.49 | 539,600 |
| 2021-03-12 | Solomons Neil (Chief Medical Officer) | Option Ex | 40,000 | 3.02 | 120,800 |
| 2021-03-05 | Milne George M Jr | Buy | 5,000 | 13.00 | 65,000 |
| 2021-01-29 | Leversage Jill | Buy | 1,600 | 16.03 | 25,648 |
| 2021-01-29 | Hayden Michael R | Option Ex | 95,000 | 5.97 | 567,435 |
| 2021-01-28 | Robertson Stephen P. (EVP, General Counsel) | Buy | 900 | 16.14 | 14,526 |
Insider trading activities including stock purchases, stock sales, and option exercises of AUPH listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Aurinia Pharmaceuticals Inc. (symbol AUPH, CIK number 1600620) see the Securities and Exchange Commission (SEC) website.